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CXCR4 is a co-receptor along with CD4 for human immunodeficiency virus type 1 (HIV-1). We investigated the role of N-linked
glycosylation in the N-terminus of CXCR4 in binding to HIV-1 gp120 envelope glycoproteins. Gp120s from CXCR4 (X4) and CCR5 (R5)
using HIV-1 strains bound more efficiently to non-N-glycosylated than to N-glycosylated CXCR4 proteoliposomes in a CD4-dependent
manner. Similar results were observed in binding studies using non-N-glycosylated or N-glycosylated CXCR4 expressed on cells. Mutation
of the N-glycosylation site N11 in CXCR4 (N11Q-CXCR4) enhanced CD4-dependent binding of X4 and R5 gp120s and allowed more
efficient entry of viruses pseudotyped with X4 or R5 HIV-1 envelope glycoproteins. However, the binding of R5 gp120 to N11Q-CXCR4
and entry of R5 HIV-1 viruses into cells expressing N11Q-CXCR4 were 20- and 100- to 1000-fold less efficient, respectively, than the levels
achieved using X4 gp120 or X4 HIV-1 viruses. Binding of stromal cell-derived factor (SDF)-1a, the natural ligand of CXCR4, and SDF-1a-
induced signaling were reduced by the N11Q mutation. These findings demonstrate that N-glycosylation at N11 inhibits the binding of
CXCR4 to X4 and R5 HIV-1 gp120, and provide a better understanding of the structural elements of CXCR4 involved in HIV-1 Env–
co-receptor interactions.
D 2004 Elsevier Inc. All rights reserved.Keywords: Human immunodeficiency virus (HIV-1); Envelope glycoprotein (gp120); CXCR4; Paramagnetic proteoliposomes (PMPLs); N-linked
glycosylation; Stromal cell-derived factor (SDF)-1a
Introduction biological processes, CXCR4 is one of the major co-recep-CXCR4 is a seven-transmembrane G protein-coupled
receptor for the chemokine stromal cell-derived factor
(SDF)-1a. CXCR4 is expressed in a wide range of different
cell types and tissues, and plays an important role in
leukocyte trafficking, hematopoiesis, and development
(Knaut et al., 2003; Murdoch, 2000; Rossi and Zlotnik,
2000). In addition to playing an important role in various0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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(Horuk, 1999; Rossi and Zlotnik, 2000). HIV-1 entry into
target cells is initiated by a high-affinity interaction between
gp120 glycoprotein and the primary receptor CD4, which
induces a conformational change in gp120. The subsequent
interaction of CD4-bound gp120 with the appropriate che-
mokine receptor (co-receptor), either CXCR4 or CCR5,
triggers a more dramatic rearrangement of gp120 and
gp41, which leads to fusion between the viral and cellular
membranes and virus entry (Berson and Doms, 1998; Choe
et al., 1998). T-cell line (T)-tropic HIV-1 primarily uses
CXCR4 (X4) as a co-receptor, whereas macrophage (M)-
tropic HIV-1 uses CCR5 (R5).
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significantly affect HIV-1 envelope (Env)–co-receptor inter-
action and the efficiency of virus entry. Sulfation of the CCR5
N-terminus is critical for R5 HIV-1 Env binding and virus
entry, and facilitates interaction with the natural ligands MIP-
1a and MIP-1h, whereas sialylated O-glycans in the N-
terminus exert little effect on HIV-1 infection but are critical
for high affinity binding of MIP-1a and MIP-1h (Bannert et
al., 2001; Farzan et al., 1998, 1999). Like CCR5, CXCR4 is
sulfated in the N-terminus (Farzan et al., 2002). Tyrosine 21
of CXCR4 is efficiently sulfated while tyrosines 7 and 12 are
less efficiently sulfated. The sulfate group at tyrosine 21 plays
only a minor role in X4 HIV-1 entry, but contributes sub-
stantially to the ability of CXCR4 to bind SDF-1a (Farzan et
al., 2002). In some cell lines, CXCR4 is modified by a
chondroitin sulfate chain at serine 18, but neither HIV-1 entry
nor SDF-1a binding is affected by loss of this glycosamino-
glycan (Farzan et al., 2002). In contrast to CCR5, CXCR4 is
posttranslationally modified by N-linked glycosylation (Ber-
son et al., 1996; Chabot et al., 2000). There are two potential
N-linked glycosylation sites in CXCR4, asparagines 11 and
176 (N11 and N176). Chabot et al. (2000) demonstrated that
CXCR4 with mutations at both N11 and N176 had the same
molecular mass as CXCR4 with the N11 mutation alone,
suggesting that N11 is the only glycosylation site used.
Mutation of N11 and N176 did not show a significant effect
on X4 HIV-1 infection in this study or other previous studies
(Brelot et al., 2000; Picard et al., 1997; Thordsen et al., 2002).
However, Chabot et al. (2000) demonstrated that mutation of
N11 and N176 in CXCR4 allows it to function as a co-
receptor for R5 HIV-1. Thordsen et al. (2002) reported that
mutation of N11 and N176 in CXCR4 facilitates infection by
R5X4 HIV-1, but does not support infection by R5 HIV-1.
Thus, further studies are required to clarify the role of
glycosylation of CXCR4 in gp120–CXCR4 interactions.
In the present study, we utilize purified CXCR4 recon-
stituted on paramagnetic proteoliposomes (PMPLs) and other
approaches to demonstrate thatN-glycosylation of CXCR4 at
N11 inhibits X4 and R5HIV-1 gp120 binding and virus entry,
but facilitates binding to the natural ligand SDF-1a.Results
Enhanced binding of HIV-1 gp120 to de-glycosylated CXCR4
reconstituted on proteoliposomes and CXCR4 expressed on
tunicamycin-treated cells
Previous studies demonstrated that CXCR4 is posttrans-
lationally modified by N-linked glycosylation (Berson et al.,
1996; Chabot et al., 2000). To investigate the role of N-
glycosylation in the binding of CXCR4 to HIV-1 gp120, we
employed several approaches. We previously demonstrated
that CXCR4 displayed on paramagnetic proteoliposomes
(PMPLs) maintains a native, membrane-associated confor-
mation that allows the convenient study of purified CXCR4(Babcock et al., 2001; Mirzabekov et al., 2000). PMPLs
have several advantages over receptor-expressing cells,
including feasibility for biochemical modification of mem-
brane-bound proteins without concerns about cell toxicity,
and higher specificity for protein–protein interactions.
CXCR4-PMPLs were prepared and used to assess the
binding of CXCR4 to gp120. CXCR4-PMPLs were either
untreated or were treated with N-glycosidase F (N-gly) to
prepare de-glycosylated CXCR4-PMPLs. In the absence of
sCD4, there was negligible binding of either HXBc2 or JR-
FL gp120 to untreated CXCR4-PMPLs (Figs. 1A and B). N-
gly treatment slightly increased HXBc2 gp120 binding to
CXCR4-PMPLs in the absence of sCD4. In the presence of
sCD4, HXBc2 gp120 bound untreated CXCR4-PMPLs in a
dose-dependent manner. HXBc2 gp120 binding increased
by approximately 3-fold when N-gly-treated CXCR4-
PMPLs were used (Fig. 1A). There was no significant
binding of HXBc2 gp120 to CCR5-PMPLs in the presence
of sCD4 (data not shown). In the presence of sCD4, JR-FL
gp120 bound to CXCR4-PMPLs at levels similar to that of
HXBc2 gp120 (Fig. 1B), but demonstrated no binding to
PMPLs with Duffy antigen/receptor for chemokine (DARC)
(Duffy-PMPLs) (data not shown). This unexpected result
may reflect some conformational similarity between
CXCR4 and CCR5. In addition, the Env binding site may
be more accessible for sCD4-bound JR-FL gp120 in
CXCR4 incorporated into PMPLs compared to CXCR4
expressed on the cell surface, possibly because the confor-
mation of CXCR4 reconstituted in PMPLs is more relaxed
than that of CXCR4 expressed on the cell surface. JR-FL
gp120 exhibited up to 2-fold more binding to N-gly-treated
CXCR4-PMPLs than to untreated CXCR4-PMPLs in the
presence of sCD4. Similar results were obtained with gp120
proteins from the HIV-1 X4 strain MN (ImmunoDiagnostics
Inc. Woburn, MA), and R5 strains ADA and YU2 (data not
shown). N-gly treatment of CXCR4-PMPLs resulted in de-
glycosylated CXCR4-PMPLs as confirmed by Western
blotting (Fig. 1C), but did not have a significant effect on
CXCR4 expression levels as determined by flow cytometric
analysis (data not shown). These results suggest that N-
glycosylation of CXCR4 reduces its ability to bind to both
X4- and R5-tropic HIV-1 gp120.
We also tested whether non-N-glycosylated CXCR4
expressed on cell membranes binds HIV-1 gp120 with
higher efficiency compared to N-glycosylated CXCR4.
The specificity of gp120 binding to Cf2Th-CXCR4 cells
was confirmed using AMD3100, a CXCR4 small molecule
antagonist (Labrosse et al., 1998), which reduced binding of
HXBc2 gp120 to Cf2Th-CXCR4 cells by more than 80%
(Fig. 1D). Stable Cf2Th transfectants expressing CXCR4
were cultured in the absence or presence of tunicamycin, an
inhibitor of N-glycosylation, and then used for gp120
binding assays. As shown in Figs. 1E and F, both X4 and
R5 gp120 bound to tunicamycin-treated Cf2Th-CXCR4
cells with higher efficiency compared to untreated cells.
CD4-dependent binding of JR-FL gp120 to non-N-glycosy-
Fig. 1. Enhanced binding of gp120 to non-N-glycosylated CXCR4. CXCR4 proteoliposomes (CXCR4-PMPLs) were either untreated or treated with N-
glycosidase F (N-gly), and used for X4 and R5 gp120 binding assays (A and B) as described in Materials and methods. In parallel, untreated and N-gly-treated
CXCR4-PMPLs were examined by Western blotting (C) to monitor the quality of CXCR4-PMPL preparations. Cf2Th-CXCR4 cells were pre-incubated with
or without 1 AM AMD3100 at 37 jC for 20 min, and then incubated with sCD4 alone or HXBc2 gp120 and sCD4 for gp120 binding assays (D), or Cf2Th-
CXCR4 cells were cultured in the presence or absence of tunicamycin for 2 days, and then harvested for gp120 binding assays (E and F). Results shown are
representative of two or three independent experiments.
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lower compared with binding of HXBc2 gp120 (Figs. 1E
and F). Enhanced gp120 binding did not seem to be caused
by changes in CXCR4 expression levels, particularly for
HXBc2 binding, because tunicamycin treatment upregulated
CXCR4 expression by less than 30% (data not shown),
whereas HXBc2 gp120 binding was enhanced by up to 5-
fold. Taken together, these results provide further support
for the conclusion that N-glycosylation of CXCR4 reduces
its ability to bind to HIV-1 gp120.
Asparagine 11 is the only site used for N-glycosylation of
CXCR4
Chabot et al. (2000) previously demonstrated that N11 of
CXCR4 is the only glycosylation site used in mammaliancells. To investigate whether N-glycosylation of CXCR4
plays a role in gp120 binding, we generated a point mutant
in which asparagine 11 was changed to glutamine (N11Q-
CXCR4), and a N-terminal truncated form of CXCR4 in
which 24 amino acids (2–25) in the N-terminus of CXCR4
were deleted (DN-CXCR4). Stable Cf2Th transfectants
expressing either wild-type CXCR4 or these mutated forms
of CXCR4 were established. Cell surface CXCR4 was
immunoprecipitated and then detected by Western blotting.
The predominant form of CXCR4 at around 45 kDa is likely
the N-glycosylated form (Fig. 2) (Chabot et al., 2000). The
lower band at around 34 kDa was not recognized by the
polyclonal antibody against the CXCR4 N-terminus. There-
fore, this form is most likely an N-terminus truncated form of
CXCR4. This truncated form of CXCR4 is likely to be
generated artefactually during cell lysis through the action
Fig. 2. Glycosylation of CXCR4 at N11. Stable Cf2Th transfectants expressing the indicated CXCR4 variants were cultured in the presence or absence of
tunicamycin for 2 days. Surface CXCR4 was then immunoprecipitated from these cells and subjected to Western blotting as described in Materials and
methods. The membrane was first blotted with rabbit anti-CXCR4 N-terminus, and then re-blotted with anti-C9 (1D4) and anti-myc (9E10) mAbs after
stripping. Results shown are representative of two independent experiments.
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increase in this form occurred in some preparations of
CXCR4-PMPLs following prolonged storage at 4 jC (data
not shown). Themiddle band at around 40–41 kDa is close to
the predicted molecular mass of CXCR4 based on amino acid
sequence and is likely the non-N-glycosylated form of
CXCR4 (Chabot et al., 2000). DN-CXCR4 immunoprecipi-
tated from Cf2Th-DN-CXCR4 cells treated with tunicamycin
exhibited a similar molecular mass at around 34 kDa com-
pared to DN-CXCR4 from untreated cells, suggesting that
only the N-terminus of CXCR4 contains an N-glycosylation
site that is actually used (Fig. 2). Furthermore, myc-tagged
N11Q-CXCR4 immunoprecipitated from Cf2Th-N11Q-
CXCR4 cells demonstrated a markedly reduced molecular
mass (around 41 kDa) compared to myc-tagged wild-type
CXCR4 (around 45 kDa). These results confirm that N11 is
the only site used for glycosylation of CXCR4.
Effects of CXCR4 N11Q mutation and truncation of the
CXCR4 N-terminus on HIV-1 gp120 and SDF-1a binding
To determine the effects of N11Q mutation and trunca-
tion of the N-terminus on CXCR4 function, stable Cf2Th
transfectants expressing N11Q-CXCR4 (Figs. 3A and B)
and DN-CXCR4 (Figs. 3E and F) were used for gp120
binding assays. Similar to results obtained using CXCR4-
PMPLs and tunicamycin-treated cells, HXBc2 gp120
exhibited greater than 4-fold more binding to Cf2Th cells
expressing N11Q-CXCR4 compared to Cf2Th cellsexpressing wild-type CXCR4 (Fig. 3A). JR-FL gp120 also
exhibited up to 1.5-fold more binding to Cf2Th cells
expressing N11Q-CXCR4 compared to Cf2Th cells
expressing wild-type CXCR4 (Fig. 3B). This effect was
not due to difference in CXCR4 expression levels on
transfected Cf2Th cells because the two stable cell lines
expressed comparable levels of CXCR4 on the cell surface
(data not shown). These results suggest that N-glycosyla-
tion of CXCR4 inhibits HIV-1 gp120 binding to CXCR4.
CD4-dependent binding of JR-FL gp120 to N11Q-CXCR4
was nearly 20-fold weaker compared with HXBc2 gp120
(Figs. 3A and B), suggesting that non-N-glycosylated
CXCR4 binds R5 gp120 much less efficiently compared
to X4 gp120. The binding of HXBc2 gp120 to Cf2Th cells
expressing DN-CXCR4 was similar compared to binding to
cells expressing wild-type CXCR4, except at the highest
gp120 concentration, where a slight reduction in binding
was observed (Fig. 3E). Similar results were observed
using MN gp120 (data not shown). The binding of JR-
FL gp120 to Cf2Th cells expressing DN-CXCR4 was
similar compared to binding to cells expressing wild-type
CXCR4 (Fig. 3F). Cf2Th-DN-CXCR4 and Cf2Th-CXCR4
cells expressed comparable levels of CXCR4 on their
surface (data not shown). These results suggest that dele-
tion of the N-terminus of CXCR4 diminishes the enhancing
effect of the glycan removal at N11 on gp120 binding,
indicating that the intact structure or specific residues of the
CXCR4 N-terminus may facilitate optimal gp120–CXCR4
interaction.
Fig. 3. Effects of CXCR4 N11Q mutation and truncation of the CXCR4 N-terminus on gp120 and SDF-1a binding. Stable Cf2Th transfectants expressing
wild-type CXCR4, N11Q-CXCR4 (A–C), or DN-CXCR4 (D–F) were used for gp120 (A, B, E, and F) or SDF-1a-Ig (C and D) binding assays. Results shown
are representative of two to five independent experiments.
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truncation of the N-terminus on CXCR4 binding to its
natural ligand, SDF-1a. To facilitate detection, SDF-1a
fused with the Fc portion of human IgG1 (SDF-1a-Ig)
was used (Babcock et al., 2001). Cells were incubated with
SDF-1a-Ig, and bound SDF-1a-Ig was detected by staining
with anti-human IgG pAb. The binding of SDF-1a-Ig to
Cf2Th cells expressing N11Q-CXCR4 is 50% less efficient
compared to the binding to cells expressing wild-type
CXCR4 (Fig. 3C), whereas SDF-1a-Ig was unable to bind
to Cf2Th cells expressing DN-CXCR4 (Fig. 3D). This result
suggests that N-glycosylation of CXCR4 is important for
optimal binding to SDF-1a, whereas the N-terminus of
CXCR4 is essential for binding to SDF-1a.
Effects of N-glycosylation of CXCR4 on HIV-1 entry
To test whether N-glycosylation of CXCR4 affects its
ability to function as an HIV-1 co-receptor, an HIV-1 entryassay was performed. Luciferase reporter viruses pseudo-
typed with X4 (HXBc2 and SG3) or R5 (ADA) HIV-1
envelopes were used to infect stable Cf2Th transfectants
expressing either N11Q- or wild-type CXCR4 in the ab-
sence or presence of sCD4. In the presence of sCD4, Cf2Th
cells expressing N11Q-CXCR4 supported entry of viruses
pseudotyped with X4 HXBc2 and SG3 Envs at about 3.5-
and 2-fold higher efficiency, respectively, compared to cells
expressing wild-type CXCR4 (Fig. 4A), whereas both cell
lines supported comparable levels of entry with viruses
pseudotyped with VSV-G Env. Viruses pseudotyped with
R5 ADA Env could not infect Cf2Th cells expressing wild-
type CXCR4, whereas a low level of entry into cells
expressing N11Q-CXCR4 was observed (Fig. 4B). In con-
trast, infection of Cf2Th cells expressing CCR5 was com-
parable to that of SG3 infection of Cf2Th cells expressing
wild-type CXCR4 (data not shown). Less than 0.1% of cells
expressing N11Q-CXCR4 were infected with ADA plus
sCD4 based on FACS analysis of infected cells stained with
Fig. 4. Effects of N-glycosylation of CXCR4 on HIV-1 entry. Stable Cf2Th-CXCR4 wild-type or N11Q mutant transfectants were infected with replication-
defective luciferase reporter viruses pseudotyped with no Env or Env from VSV-G, or HIV-1 HXBc2, SG3, or ADA in the presence or absence of sCD4
(A and B), or infected with reporter viruses pseudotyped with SG3 Env in the presence of sCD4 and the indicated concentrations of SDF-1a, SDF-1a-Ig,
or 1 AM AMD3100 (C) as described in Materials and methods. Two days postinfection, cells were lysed and luciferase activity was measured. Results
shown are representative of two (B and C) or four (A) independent experiments. Error bars represent the SEM. a denotes that SDF-1a-Ig was used instead
of SDF-1a. * denotes Student’s t test, P < 0.05.
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(data not shown), confirming a very low level of infection.
These results suggest that N-glycosylation of CXCR4 inhib-
its CXCR4-mediated infection of cells with both X4 and R5
HIV-1. In addition, the very low level of R5 HIV-1 entry
(approximately 100- to 1000-fold lower compared to X4
HIV-1) into cells expressing N11Q-CXCR4 suggests that
non-N-glycosylated CXCR4 mediates entry of R5 HIV-1
much less efficiently compared to X4 HIV-1.
The preceding experiments suggest that removal of the
N-glycan linked to N11 facilitated gp120 binding and HIV-1
entry but impaired SDF-1a binding, raising the possibility
that removal of the CXCR4 N-glycan may result in reduced
sensitivity of HIV-1 to SDF-1a-mediated inhibition of viral
entry. To explore this possibility, luciferase reporter virus
pseudotyped with the SG3 envelope was used to infect
stable Cf2Th transfectants expressing wild-type CXCR4 or
N11Q-CXCR4 in the presence of sCD4 and varied concen-
trations of SDF-1a. The inhibitory effect of SDF-1a on
HIV-1 entry was dose-dependent (Fig. 4C). SDF-1a reduced
the entry of virus pseudotyped with SG3 envelope into
Cf2Th cells expressing wild-type CXCR4 by 99.8% at 250
nM, whereas entry of virus into Cf2Th cells expressingN11Q-CXCR4 under identical conditions was inhibited by
only 72.1%. Virus entry into cells expressing either wild-
type CXCR4 or N11Q-CXCR4 was completely blocked by
a higher dose (1250 nM) of SDF-1a-Ig or by 1 AM
AMD3100, confirming that viral entry was mediated by
CXCR4. These results suggest that N-glycosylation of
CXCR4 increases the sensitivity of HIV-1 to SDF-1a-
mediated inhibition of viral entry, presumably by hindering
CXCR4–gp120 interactions or enhancing CXCR4–SDF-
1a interactions.
Effects of N-glycosylation of CXCR4 on SDF-1a-induced
signaling
To test whether N-glycosylation of CXCR4 affects the
signal transduction function for its natural ligand SDF-1a,
we tested SDF-1a-induced calcium mobilization in stable
Cf2Th transfectants expressing either wild-type CXCR4 or
N11Q-CXCR4 (Fig. 5). Corresponding to the results
obtained in SDF-1a binding assays, SDF-1a-Ig induced
weaker calcium signaling in cells expressing non-N-glyco-
sylated CXCR4 (N11Q-CXCR4) compared to cells express-
ing wild-type CXCR4. Together with the SDF-1a-Ig
Fig. 5. Effects of N-glycosylation of CXCR4 on SDF-1a-induced calcium mobilization. Stable Cf2Th-CXCR4 wild-type or N11Q mutant transfectants were
loaded with Fluo-3 for measurement of calcium influx as described in Materials and methods. Calcium influx is displayed as a ratio between the measurement
at the indicated time point after stimulation and the background measurement in the absence of stimulant. Time (s) 0 indicates the time points when SDF-1a-Ig
was added. Results shown are representative of three independent experiments.
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CXCR4 is important for optimal binding to SDF-1a and
subsequent signaling.Discussion
Herein we provide evidence that N-glycosylation of the
N-terminus inhibits CXCR4 binding to gp120 and HIV-1
entry, but enhances binding to SDF-1a. We found that non-
N-glycosylated CXCR4, either expressed on cells or recon-
stituted on PMPLs, bound to R5 and X4 gp120 more
efficiently compared to wild-type CXCR4, suggesting that
N-glycosylation of the CXCR4 N-terminus has an inhibitory
effect on the gp120–CXCR4 interaction. Removal of the
CXCR4 N-terminus (amino acids 2–25) diminished the
enhancing effect of N11 glycan removal on gp120 binding,
suggesting that the intact structure or specific residues of the
CXCR4 N-terminus may facilitate optimal gp120–CXCR4
interaction. In addition, the low levels of binding of R5
gp120 to N11Q-CXCR4 and entry of R5 HIV-1 into N11Q-
CXCR4-expressing cells suggest that non-N-glycosylated
CXCR4 interacts weakly with R5 HIV-1 gp120s.
The interactions of CCR5 and CXCR4 with gp120 are
topologically complex (Berson and Doms, 1998; Choe et
al., 1998; Horuk, 1999). In the case of CCR5, a tyrosine-
and aspartic acid-enriched sequence in the N-terminus
(amino acids 10–15, the YDINYY motif) plays a critical
role in co-receptor function (Choe et al., 1998; Farzan et al.,
1998, 1999). In contrast to CCR5, the N-terminus ofCXCR4 is less important than the first and second extra-
cellular loops for co-receptor function (Brelot et al., 1997;
Doranz et al., 1999; Horuk, 1999; Picard et al., 1997).
CXCR4 has a relatively low affinity for CD4-bound X4
gp120. The calculated dissociation constant of approximate-
ly 200 nM is nearly 100-fold lower than that of CCR5 for
CD4-bound R5 gp120 (Babcock et al., 2001). Hence, the
formation of a stable CD4-gp120–CXCR4 complex may be
facilitated by supporting interactions between the N-termi-
nus of CXCR4 and gp120. In the present study, we
demonstrated that non-N-glycosylated CXCR4, either
expressed on cells or reconstituted on PMPLs, bound to
gp120 more efficiently compared to wild-type CXCR4 in a
CD4-dependent manner. This finding suggests that the
glycan in CXCR4 N-terminus may function as a steric as
well as electrostatic hindrance for gp120 binding, and
removal of the glycan may make CXCR4 more accessible
for gp120 binding. However, removal of the CXCR4 N-
terminus (amino acids 2–25) diminished the enhancing
effect of N11 glycan removal alone on gp120 binding.
Farzan et al. (2002) previously demonstrated that mutation
of the three tyrosine residues at Y7, Y12, and Y21 inhibited
CXCR4-mediated entry of some HIV-1 strains. Thus, other
types of posttranslational modifications in the CXCR4 N-
terminus, such as tyrosine sulfation, may also modulate
gp120–CXCR4 interactions. Removal of the sialic acid
moiety by neuraminidase treatment from CXCR4 enhanced
CD4-dependent X4 gp120 binding to Cf2Th cells express-
ing wild-type CXCR4 and N11Q-CXCR4 to a similar extent
(data not shown). Thus, sialic acid modification of the N-
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its hindrance effect on gp120 binding.
In addition to X4 gp120 binding, X4 HIV-1 entry was
enhanced by 2- to 3.5-fold in cells expressing non-N-
glycosylated CXCR4 (N11Q-CXCR4) compared with
wild-type CXCR4, suggesting that N-glycosylation modu-
lates CXCR4 co-receptor function. By mutation of the
potential N-glycosylation sites of CXCR4, an inhibitory
effect of N-glycosylation of CXCR4 was demonstrated for
CD4-independent infection by HIV-2 (Potempa et al.,
1997). Chabot et al. (2000) demonstrated that CXCR4 is
posttranslationally modified by N-glycosylation at N11, but
did not observe a significant effect of N-glycosylation of
CXCR4 on X4 HIV-1 infection. The inhibitory effect of N-
glycosylation of CXCR4 on X4 HIV-1 infection was also
not observed in other previous studies in which potential N-
glycosylation sites of CXCR4 were mutated (Brelot et al.,
2000; Picard et al., 1997; Thordsen et al., 2002). Discrep-
ancies among these studies are likely due to several possible
factors. First, the experimental systems used in these studies
such as the choice of HIV-1 strains, fusion vs. single-round
infection assays, cell lines, or differences in receptor density
of CD4 and CXCR4 may cause different results. Second,
there may be substituted amino acid-dependent effects
[N11Q vs. N11I (Picard et al., 1997) vs. N11A (Chabot et
al., 2000)]. N11Q-CXCR4 is structurally more similar to
wild-type CXCR4 because glutamine (Q) and asparagine
(N) are both amino acids with uncharged polar side chains.
In addition, it is possible that simultaneous substitution of
N176 in the second extracellular loop of CXCR4 with
another amino acid (such as alanine) may result in changes
in co-receptor function even if this residue is not N-glyco-
sylated (Chabot et al., 2000). Third, non-N-glycosylated
CXCR4 may have a reduced ability to associate with CD4
on the cell surface, because treatment of cells with N-
glycanase was shown to reduce co-association between
these two proteins (Mbemba et al., 2002).
The N11Q mutation in CXCR4 allowed R5 HIV-1 gp120
to bind to CXCR4, albeit inefficiently. Similarly, de-glyco-
sylation of CXCR4-PMPLs enhanced binding to R5 gp120.
These findings suggest that removal of the N-glycan
unmasks a conserved structure shared by CXCR4 and
CCR5 that is important for gp120 binding. We found that
CD4-dependent binding of R5 gp120 to non-N-glycosylated
N11Q-CXCR4 was 20-fold lower compared with X4 gp120
(Figs. 3A and B), and non-N-glycosylated N11Q-CXCR4
supported only a low level of R5 HIV-1 entry (approximately
100- to 1000-fold lower compared to X4 HIV-1) (Figs. 4A
and B). Chabot et al. (2000) demonstrated that mutation of
potential N-glycosylation sites N11 and N176 in CXCR4
allowed it to function as a co-receptor for R5 HIV-1 almost
as potently as wild-type CCR5 in h-galactosidase-based
cell–cell fusion assays using U373 cells expressing recom-
binant vaccinia virus-encoded CD4 and co-receptors. How-
ever, consistent with our data, the same mutation in CXCR4
allowed entry of R5 HIV-1 at 50- to 1000-fold lower levelscompared to wild-type CCR5 in luciferase-based HIV-1
infection assays using U373 CD4+ cells transfected with
co-receptor expressing pCDNA3 plasmids (Chabot et al.,
2000). Thus, the strong co-receptor function of non-N-
glycosylated CXCR4 for R5 HIV-1 demonstrated by Chabot
et al. in cell–cell fusion assays was not observed under
conditions that more closely mimic natural HIV-1 infection.
Taken together, these findings suggest that non-N-glycosy-
lated CXCR4 can function as a co-receptor for R5 HIV-1
entry, but the entry process is extremely inefficient. This may
help to explain why Thordsen et al. (2002) observed that
CXCR4 with mutations at N11 and N176 facilitated infec-
tion by R5X4 HIV-1, but did not support infection by R5
HIV-1. It remains to be determined whether such low levels
of R5 HIV-1 entry mediated by non-N-glycosylated CXCR4
play any role in HIV-1 infection in vivo.
In contrast to its inhibitory effect on HIV-1 Env binding,
glycosylation at N11 of CXCR4 enhanced binding to its
natural ligand, SDF-1a. Similar results were previously
observed in insect cells expressing human CXCR4 (Zhou
and Tai, 1999). These results are not surprising because it is
known that SDF-1a associates with glycans and glycosa-
minoglycans (Mbemba et al., 1999, 2000). Furthermore, the
residues of SDF-1a that interact with heparan sulfates and
heparin have been defined (Amara et al., 1999; Sadir et al.,
2001). Therefore, it is likely that the carbohydrate chain at
N11 of CXCR4 provides additional binding sites for SDF-
1a that increase the affinity of the CXCR4–SDF-1a inter-
action and enhance subsequent signaling (Figs. 3 and 5). In
contrast to the critical role of sialic acid moieties of O-linked
oligosaccharides in the CCR5 N-terminus in MIP-1a and
MIP-1h binding (Bannert et al., 2001), removing the sialic
acid moiety linked to the N-glycan at N11 did not appear to
have a significant effect on SDF-1a binding, because
neuraminidase treatment reduced SDF-1a-Ig binding to
Cf2Th cells expressing wild-type or N11Q-CXCR4 to a
similar extent (data not shown). Thus, sialic acid modifica-
tion appears to be more important for CCR5 than for
CXCR4 binding to chemokine ligands.
In conclusion, our study underscores the inhibitory role
of the glycan linked to N11 within the CXCR4 N-terminus
in X4 and R5 gp120 binding and HIV-1 entry, and its
enhancing role in SDF-1a binding and subsequent signal
transduction. The findings help to elucidate structural ele-
ments of CXCR4 involved in HIV-1 Env–co-receptor
interactions. A better understanding of these interactions
will facilitate the development of therapeutic approaches to
inhibit virus entry.Materials and methods
Cell culture and preparation of stable CXCR4 transfectants
The canine thymus-derived cell line Cf2Th and human
embryonic kidney cell line 293Twere maintained in DMEM
J. Wang et al. / Virology 324 (2004) 140–150148(Life Technologies) supplemented with 2 mM glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, and 10% (v/
v) heat-inactivated fetal bovine serum (FBS) (Sigma).
Stably transfected CXCR4-expressing Cf2Th cells (Cf2Th-
CXCR4) were generated by transfection with one of the
following codon-optimized CXCR4 (synCXCR4) plasmids:
pcDNA3-synCXCR4-C9 (Babcock et al., 2001), pcDNA3-
synCXCR4-DN-C9, pcDNA3-synCXCR4-myc (Farzan et
al., 2002), and pcDNA3-synCXCR4-N11Q-myc. A se-
quence encoding the rhodopsin C9 (TETSQVAPA) or myc
(EQKLISEEDL) peptide was introduced immediately 5V to
the natural stop codon for CXCR4. The plasmids were
designed as described previously for CCR5 (Mirzabekov
et al., 1999). Transfected cells were selected by maintaining
cells in the presence of 0.5 mg/ml G418. Stable cell lines
expressing comparable levels of CXCR4 were obtained by
cell sorting with a MoFlo cell sorter (Cytomation).
Immunoprecipitation and Western blotting
To immunoprecipitate CXCR4, cells were incubated with
the anti-CXCR4 monoclonal antibody (mAb) RD17 (R&D
Systems, clone 44717.111) at 4 jC for 30 min and washed.
Cells were then lysed with solubilization buffer [1%
CHAPSO (Anatrace), 100 mM (NH4)2SO4, 20 mM Tris–
HCl (pH 8.5), and 10% glycerol] containing a cocktail of
Complete Protease Inhibitor mixture (Roche Molecular
Biochemicals) and clarified by centrifugation. CXCR4 in
cell lysates was precipitated with protein A sepharose and
washed four times. Samples were eluted by adding an equal
volume of 2 sample loading buffer [0.1 M dithiothreitol,
4% SDS, 0.2% bromophenol blue, 0.1 M Tris–HCl (pH
6.8), and 20% Glycerol] and incubating at 37 jC for 30–60
min, and then run on 11% SDS-PAGE gels before transfer-
ring to PVDF membranes for Western blotting. Membranes
were blotted with a rabbit anti-CXCR4 N-terminus poly-
clonal antibody (pAb) (BioChain Institute), a mouse mAb
(1D4) against the C9 peptide tag (National Cell Culture
Center), or a mouse mAb (10E9) against the myc peptide
tag (National Cell Culture Center), followed by incubation
with horseradish peroxidase (HRP)-conjugated F(abV)2 frag-
ment of donkey Ig against rabbit IgG or F(abV)2 fragment of
sheep Ig against mouse IgG (Amersham Pharmacia), and
developing with NEN Western Lightning Chemilumines-
cence Reagents (Perkin-Elmer).
Synthesis of CXCR4-containing paramagnetic
proteoliposomes (CXCR4-PMPLs)
CXCR4-PMPLs were prepared as described previously
(Babcock et al., 2001). Briefly, Cf2Th-CXCR4 cells
expressing C9-tagged CXCR4 were lysed and incubated
with paramagnetic M-280 Dynal beads coated with the 1D4
antibody overnight at 4 jC. Beads were washed with
solubilization buffer and incubated for 8 h in buffer con-
taining 1% CHAPSO, 20% glycerol, 100 mM (NH4)2SO4,20 mM Tris, pH 7.5, and 0.1% (w/v) lipid mixture (60% 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 30% 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, and
10% 1,2-dioleoyl-sn-glycero-3-phosphate) (Avanti Polar
Lipids). The solution was then dialyzed for 16 h at 4 jC
using a 10-kDa molecular weight cut-off Slide-A-Lyzer
(Pierce) to remove detergent and allow the formation of
proteoliposomes. Proteoliposomes were then purified using
a magnetic field. The presence of CXCR4 was confirmed by
Western blotting as well as flow cytometry analysis.
Enzymatic de-glycosylation of CXCR4
To prepare de-glycosylated CXCR4-PMPLs, CXCR4-
PMPLs were incubated with 40 U/ml (equivalent to 40
IUB mU/ml) N-glycosidase F (N-gly) (Sigma) in 50 mM
Na2HPO4 (pH 7.5) for 3 h at 37 jC, and then washed. The
quality of de-glycosylated CXCR4-PMPLs preparations
was examined by flow cytometry analysis after staining
with anti-CXCR4 mAb 12G5 or RD17, and by Western blot
analysis.
HIV-1 gp120 and SDF-1a binding assays
HXBc2 and JR-FL gp120s were purified from the culture
supernatant of 293T cells transiently transfected with the
pSVIIIexE7 plasmid containing the corresponding gp120
sequences as described previously (Babcock et al., 2001)
using a F105 (anti-gp120 mAb) affinity column. To exam-
ine gp120 binding, CXCR4-PMPLs or cell lines stably
expressing CXCR4 (Cf2Th-CXCR4) were incubated with
gp120, which had been pre-incubated in the presence or
absence of 5–25 Ag/ml sCD4 at 37 jC for 30–60 min, at
indicated concentrations in binding buffer (2.5% FBS,
0.05% NaN3 in PBS, pH 7.4) at 37 jC for 30 min and
washed. CXCR4-PMPLs or Cf2Th-CXCR4 cells were then
incubated with a human anti-gp120 mAb (C11) at 4 jC for
30 min and washed. At the third step, CXCR4-PMPLs or
Cf2Th-CXCR4 cells were stained with PE-conjugated anti-
human IgG pAb at 4 jC for 30 min. For all staining
experiments using cells, 7-AAD (BD Pharmingen) was also
included in the staining buffer at the last staining step to
exclude non-viable cells from the analysis. Cf2Th-CXCR4
cells were then washed and fixed with PBS containing 1%
(w/v) paraformaldehyde. For experiments using CXCR4-
PMPLs, beads were washed and then suspended in binding
buffer. Stained CXCR4-PMPLs or Cf2Th-CXCR4 cells
were then analyzed using an EPICS XL flow cytometer
(Beckman Coulter).
Immunoglobulin (Ig)-tagged SDF-1a (SDF-1a-Ig) was
produced as a secreted protein by 293T transiently trans-
fected with a plasmid encoding for SDF-1a-Ig (a gift of Dr.
Timothy Springer, Center for Blood Research, Boston) as
described previously (Babcock et al., 2001). SDF-1a-Ig was
purified by sequentially using a protein A column and
heparin column. The purity and bioactivity of SDF-1a-Ig
J. Wang et al. / Virology 324 (2004) 140–150 149were confirmed by SDS-PAGE and calcium mobilization
assay, respectively. For SDF-1a binding assays, cells were
first incubated with SDF-1a-Ig at 4 jC for 30 min and
washed, and then stained with PE-conjugated antihuman
IgG pAb at 4 jC for 30 min. For experiments to determine
CXCR4 expression levels, cells were first incubated with
different concentrations of RD17 at 4 jC for 30 min and
washed, and then stained with PE-conjugated anti-mouse Ig
pAb at 4 jC for 30 min. Stained cells were then washed,
fixed, and analyzed using a flow cytometer. The amount of
ligands bound to cells was indicated by relative mean
fluorescence intensity (MFI), which is calculated as
(MFIspe  MFIcon) / MFIcon. MFIspe are MFI of cells
incubated with indicated concentrations of SDF-1a-Ig or
gp120. MFIcon are MFI of cells incubated with soluble
CD4-Ig or in the absence of gp120.
HIV-1 entry assay
Recombinant HIV-1 luciferase reporter viruses were
generated as described previously with some modifications
(Wojtowicz et al., 2002). Briefly, 293T cells were co-trans-
fected with vectors expressing the pCMVDP1DenvpA HIV-
1 Gag-Pol packaging construct, pLuc reporter construct, and
pSVIIIexE7Env or pSVIIIexE7DKSEnv (as a negative con-
trol) or pHCMV-G, and with (when pHCMV-G was used) or
without pCMV-Rev plasmid by the calcium phosphate
method. Viruses harvested from cell culture supernatants
were quantitated for reverse transcriptase (RT) activity by
incorporation of [3H]dTTP into an artificial poly(A)(dT)15
template as described (Rho et al., 1981). To examine HIV-1
entry, target cells were infected by incubation with equiva-
lent amounts of replication-defective recombinant luciferase
virus (5000–20000 3H cpm RT units per well) in the absence
or presence of 0.5–5 Ag/ml sCD4 overnight at 37 jC. In
some experiments, the indicated concentrations of SDF-1a,
SDF-1a-Ig, or 1 AM AMD3100 were included in the culture
medium. The medium was then removed and the cultures
were washed once with PBS. After an additional 48 h in
culture, cells were lysed for measurement of luciferase
activity.
Calcium mobilization assay
Dissociated cells were resuspended in 1 ml of CI buffer
[Hanks’ buffered saline solution, 10 mM HEPES (pH 7.2),
0.1% (w/v) bovine serum albumin] and incubated with 2
AM Fluo-3 (Molecular Probes Inc.) for 30 min at room
temperature. Cells were then washed twice with PBS and
resuspended in CI buffer in the presence of 1 mM MgCl2
and 0.5 mM CaCl2. Calcium flux measurements in response
to stimuli were then measured with a Victor 2 multi-label
counter (Wallac). Calcium flux index (CFI) represents the
ratio between measurements at indicated time points after
stimulation and background measurements in the absence of
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